Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Shire appoints research and development head

Shire appoints research and development head

26th November 2007

Shire has announced the appointment of Dr Whaijen Soo as senior vice-president of research and development of its human genetic therapies (HGT) business based in Cambridge, Massachusetts.

In this position, Dr Soo will have responsibility for the product portfolio of this unit, which includes preclinical research and development and clinical research, in addition to medical affairs, regulatory affairs and process development.

Dr Soo will also be a member of the senior management team for the department and play a vital role in evaluating potential business development opportunities while reporting to Slyvie Gregoire, president of the group.

Ms Gregoire said: “The Shire HGT portfolio of enzyme replacement therapies is growing rapidly and the addition of Dr Soo to our senior management team will contribute to the further maturation of our company and significant expansion our exciting pipeline.”

Dr Soo joins Shire from Biogen Idec, where he served as senior vice-president of medical research, leading worldwide clinical development of all compounds in the company’s product portfolio.

Before his tenure at Biogen Idec, Dr Soo worked at Roche for 18 years and was responsible for the successful filing of 14 drugs in the field of oncology, organ transplants and antivirals.

In February 2007, Shire announced the acquisition of New River Pharmaceuticals, which the company claimed would facilitate the realisation of the full economic value of attention deficit and hyperactivity disorder drug Vyvanse.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.